Galmed Pharmaceuticals sets 1-for-8 reverse stock split

Galmed Pharmaceuticals Ltd. approved a 1-for-8 reverse share split of its ordinary shares, consolidating every eight shares of par value NIS 1.80 into one share of par value NIS 14.40.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. approved a 1-for-8 reverse share split of its ordinary shares, consolidating every eight shares of par value NIS 1.80 into one share of par value NIS 14.40. Trading on the Nasdaq Capital Market on a post-split basis will begin on August 19, 2026.

Following the split, authorized share capital will consist of 112,500,000 ordinary shares with par value NIS 14.40 each, and issued and outstanding shares will change from 8,332,518 to approximately 1,041,565, subject to fractional treatment. Fractional shares will be rounded to the nearest whole share, and outstanding warrants and options will be adjusted proportionately.

Filing Explained

The split changes share denomination and trading mechanics, not company value by itself, while implementation remains scheduled for August 19.

As of August 14, 2026, the company says it will implement the 1-for-8 reverse split, with post-split trading scheduled to begin on August 19, 2026; the filing therefore describes a planned consolidation rather than a completed one.

Mechanically, a reverse split reduces the share count and raises the per-share price proportionally; the split itself does not change the company’s value.

Key Figures

Reverse split ratio: 1-for-8 Pre-split shares outstanding: 8,332,518 shares Post-split shares outstanding: approximately 1,041,565 shares +5 more

8 metrics

Reverse split ratio 1-for-8 Each eight ordinary shares will be consolidated into one ordinary share

Pre-split shares outstanding 8,332,518 shares Issued and outstanding ordinary shares before the reverse split

Post-split shares outstanding approximately 1,041,565 shares Issued and outstanding ordinary shares after the reverse split, subject to fractional adjustments

Authorized ordinary shares 112,500,000 shares Authorized share capital after the reverse split

Old par value NIS 1.80 per share Par value of each ordinary share before the reverse split

New par value NIS 14.40 per share Par value of each ordinary share after the 1-for-8 reverse split

Post-split trading start date August 19, 2026 First trading date of ordinary shares on Nasdaq Capital Market after implementation

New CUSIP M47238205 New CUSIP number assigned to the ordinary shares after the reverse split

Key Terms

reverse share split, fractional ordinary shares, authorized share capital, CUSIP number, +1 more

5 terms

reverse share split financial

"it will effect a reverse share split of the Company’s ordinary shares at the ratio of 1-for-8"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

fractional ordinary shares financial

"No fractional ordinary shares will be issued as a result of the reverse split"

A fractional ordinary share is a portion of a single common share, like owning a slice of a pizza rather than the whole pie. It gives an investor proportionate economic rights — such as a share of dividends and price gains or losses — allowing smaller-dollar purchases and easier diversification, though practical rights like voting or transferability can depend on the broker or platform handling the fraction.

authorized share capital financial

"the Company’s authorized share capital shall be comprised of 112,500,000 ordinary shares"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

CUSIP number financial

"The new CUSIP number for the ordinary shares will be M47238205"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

par value financial

"par value NIS 1.80 per share, shall be consolidated into one (1) ordinary share, par value NIS 14.40"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse share split did GLMD approve in August 2026?

Galmed Pharmaceuticals approved a 1-for-8 reverse share split, consolidating every eight ordinary shares into one share with a higher par value, while keeping total economic ownership proportionally unchanged for shareholders.

When will GLMD shares start trading on a post-split basis?

GLMD ordinary shares will begin trading on a post-split basis on August 19, 2026 on the Nasdaq Capital Market, reflecting the 1-for-8 reverse share split in the quoted share price and share count.

How does the GLMD reverse split affect shares outstanding?

The reverse split will adjust issued and outstanding GLMD shares from 8,332,518 to approximately 1,041,565. This is an 8-fold reduction in share count, consistent with the 1-for-8 consolidation ratio applied across all ordinary shares.

What happens to GLMD fractional shares in the reverse split?

No fractional ordinary shares will be issued. Fractional positions will be rounded to the nearest whole share, and only holders with fractional consolidated shares of more than one half of a whole share will receive one consolidated share.

How will GLMD warrants and options be adjusted after the split?

All outstanding GLMD warrants and options will receive a proportionate adjustment to both the per-share exercise price and the number of shares issuable upon exercise, maintaining the economic terms after the 1-for-8 reverse share split.

Did GLMD change its authorized share capital in the reverse split?

Yes. After the reverse split, authorized share capital will consist of 112,500,000 ordinary shares with a par value of NIS 14.40 per share, replacing the prior structure based on the NIS 1.80 par value shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:33 PM Accepted by SEC EDGAR 08/14/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of August 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Galmed Pharmaceuticals Ltd. (the “Company”) is announcing that it will effect a reverse share split of the Company’s ordinary shares at the ratio of 1-for-8, such that each eight (8) ordinary shares, par value NIS 1.80 per share, shall be consolidated into one (1) ordinary share, par value NIS 14.40. The first date when the Company’s ordinary shares will begin trading on the Nasdaq Capital Market after implementation of the reverse split will be Wednesday, August 19, 2026.

Following the implementation of the reverse split, the Company’s authorized share capital shall be comprised of 112,500,000 ordinary shares, par value NIS 14.40 per share. The reverse split will adjust the number of issued and outstanding ordinary shares of the Company from 8,332,518 ordinary shares to and approximately 1,041,565 ordinary shares (subject to any further adjustments based on the treatment of fractional shares).

No fractional ordinary shares will be issued as a result of the reverse split. All fractional ordinary shares will be rounded to the nearest whole ordinary share, such that only shareholders holding fractional consolidated shares of more than one half of one whole share shall be entitled to receive one consolidated share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding warrants and options entitling the holders to purchase ordinary shares. The new CUSIP number for the ordinary shares will be M47238205.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: August 14, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer